SE502989C2 - Användning av en inositoltrisfosfatester för beredning av läkemedel - Google Patents

Användning av en inositoltrisfosfatester för beredning av läkemedel

Info

Publication number: SE502989C2
Authority: SE; Sweden
Prior art keywords: inositol; trisphosphate; ester; myo; hiv
Prior art date: 1993-11-22

Application number

SE9303853A

Other languages

English (en)

Swedish (sv)

Other versions

SE9303853D0 (sv

SE9303853L (sv

Inventor

Matti Siren

Original Assignee

Perstorp Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-11-22

Filing date

1993-11-22

Publication date

1996-03-04

1993-11-22 Application filed by Perstorp Ab filed Critical Perstorp Ab

1993-11-22 Priority to SE9303853A priority Critical patent/SE502989C2/sv

1993-11-22 Publication of SE9303853D0 publication Critical patent/SE9303853D0/xx

1994-11-18 Priority to AU10816/95A priority patent/AU1081695A/en

1994-11-18 Priority to PCT/SE1994/001091 priority patent/WO1995014475A1/en

1994-11-18 Priority to US08/648,175 priority patent/US5846957A/en

1994-11-18 Priority to DE69432124T priority patent/DE69432124D1/de

1994-11-18 Priority to JP51499095A priority patent/JP3769011B2/ja

1994-11-18 Priority to AT95901674T priority patent/ATE232387T1/de

1994-11-18 Priority to EP95901674A priority patent/EP0730459B1/de

1995-05-23 Publication of SE9303853L publication Critical patent/SE9303853L/

1996-03-04 Publication of SE502989C2 publication Critical patent/SE502989C2/sv

Links

239000003814 drug Substances 0.000 title claims abstract description 19
150000002148 esters Chemical class 0.000 title claims abstract description 9
CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title claims description 22
238000002360 preparation method Methods 0.000 title claims description 16
MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 title claims description 9
229940079593 drug Drugs 0.000 title description 11
201000010099 disease Diseases 0.000 claims abstract description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
230000001177 retroviral effect Effects 0.000 claims abstract description 4
-1 inositol trisphosphate ester Chemical class 0.000 claims description 20
208000030507 AIDS Diseases 0.000 claims description 9
229960000367 inositol Drugs 0.000 claims description 9
150000003839 salts Chemical group 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 6
239000008187 granular material Substances 0.000 claims description 5
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
239000011575 calcium Substances 0.000 claims description 3
229910052791 calcium Inorganic materials 0.000 claims description 3
239000000725 suspension Substances 0.000 claims description 3
208000012124 AIDS-related disease Diseases 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
150000003751 zinc Chemical class 0.000 claims 1
210000004027 cell Anatomy 0.000 description 27
125000000217 alkyl group Chemical group 0.000 description 23
241000725303 Human immunodeficiency virus Species 0.000 description 18
208000015181 infectious disease Diseases 0.000 description 18
125000000753 cycloalkyl group Chemical group 0.000 description 15
125000003118 aryl group Chemical group 0.000 description 13
125000004432 carbon atom Chemical group C* 0.000 description 13
150000001875 compounds Chemical class 0.000 description 11
125000003710 aryl alkyl group Chemical group 0.000 description 10
MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
229910052739 hydrogen Inorganic materials 0.000 description 9
239000001257 hydrogen Substances 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
125000002877 alkyl aryl group Chemical group 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 6
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 6
229960002555 zidovudine Drugs 0.000 description 6
208000031886 HIV Infections Diseases 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
238000000034 method Methods 0.000 description 5
159000000000 sodium salts Chemical class 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
208000037357 HIV infectious disease Diseases 0.000 description 4
108010047620 Phytohemagglutinins Proteins 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
150000002431 hydrogen Chemical class 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
230000001885 phytohemagglutinin Effects 0.000 description 4
229910052717 sulfur Chemical group 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
239000011707 mineral Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000282412 Homo Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
235000010290 biphenyl Nutrition 0.000 description 2
239000004305 biphenyl Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
125000000392 cycloalkenyl group Chemical group 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
150000002391 heterocyclic compounds Chemical class 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 2
125000005499 phosphonyl group Chemical group 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
239000000047 product Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
239000011593 sulfur Chemical group 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
XJAILBPEAYQACO-UHFFFAOYSA-N 4-acetyloxybutanoyl 4-acetyloxybutanoate Chemical compound CC(=O)OCCCC(=O)OC(=O)CCCOC(C)=O XJAILBPEAYQACO-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000005024 alkenyl aryl group Chemical group 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
CDAISMWEOUEBRE-JMVOWJSSSA-N cis-inositol Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-JMVOWJSSSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 description 1
XHDPYSCXPWDZQX-UHFFFAOYSA-N ethyl-di(propan-2-yl)azanium;hydrogen phosphate Chemical compound OP([O-])([O-])=O.CC[NH+](C(C)C)C(C)C.CC[NH+](C(C)C)C(C)C XHDPYSCXPWDZQX-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
PKHMTIRCAFTBDS-UHFFFAOYSA-N hexanoyl hexanoate Chemical compound CCCCCC(=O)OC(=O)CCCCC PKHMTIRCAFTBDS-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002032 methanolic fraction Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
CDAISMWEOUEBRE-GNIYUCBRSA-N muco-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@H]1O CDAISMWEOUEBRE-GNIYUCBRSA-N 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
108010043277 recombinant soluble CD4 Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE9303853A 1993-11-22 1993-11-22 Användning av en inositoltrisfosfatester för beredning av läkemedel SE502989C2 (sv)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
SE9303853A SE502989C2 (sv)	1993-11-22	1993-11-22	Användning av en inositoltrisfosfatester för beredning av läkemedel
AU10816/95A AU1081695A (en)	1993-11-22	1994-11-18	The use of an ester of inositoltrisphosphate for the preparing of medicaments
PCT/SE1994/001091 WO1995014475A1 (en)	1993-11-22	1994-11-18	The use of an ester of inositoltrisphosphate for the preparing of medicaments
US08/648,175 US5846957A (en)	1993-11-22	1994-11-18	Use of an ester of inositoltrisphosphate for the preparing of medicaments
DE69432124T DE69432124D1 (de)	1993-11-22	1994-11-18	Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
JP51499095A JP3769011B2 (ja)	1993-11-22	1994-11-18	イノシトール三燐酸エステルの薬剤調製への使用
AT95901674T ATE232387T1 (de)	1993-11-22	1994-11-18	Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
EP95901674A EP0730459B1 (de)	1993-11-22	1994-11-18	Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9303853A SE502989C2 (sv)	1993-11-22	1993-11-22	Användning av en inositoltrisfosfatester för beredning av läkemedel

Publications (3)

Publication Number	Publication Date
SE9303853D0 SE9303853D0 (sv)	1993-11-22
SE9303853L SE9303853L (sv)	1995-05-23
SE502989C2 true SE502989C2 (sv)	1996-03-04

Family

ID=20391828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9303853A SE502989C2 (sv)	1993-11-22	1993-11-22	Användning av en inositoltrisfosfatester för beredning av läkemedel

Country Status (8)

Country	Link
US (1)	US5846957A (de)
EP (1)	EP0730459B1 (de)
JP (1)	JP3769011B2 (de)
AT (1)	ATE232387T1 (de)
AU (1)	AU1081695A (de)
DE (1)	DE69432124D1 (de)
SE (1)	SE502989C2 (de)
WO (1)	WO1995014475A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9602463D0 (sv) *	1996-06-24	1996-06-24	Perstorp Ab	The use of growth factor modulating compounds
AP9901681A0 (en) *	1997-04-09	1999-12-31	Viron Corp	Antiviral composition containing oxidized inositol, sodium sulfite, pyrocatechol and copper sulfate.
US5998485A (en) *	1997-06-16	1999-12-07	Cedars-Sinai Medical Center	Method for modulating immune response with inositol
ES2383673T3 (es) *	2000-09-22	2012-06-25	Jpi Commercial, Llc	Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
FR2828206B1 (fr) *	2001-08-03	2004-09-24	Centre Nat Rech Scient	Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7084115B2 (en)	2002-04-29	2006-08-01	Oxyplus, Inc.	Inositol pyrophosphates, and methods of use thereof
US20060258626A1 (en) *	2004-07-06	2006-11-16	Claude Nicolau	Use of inositol-tripyrophosphate in treating tumors and diseases
US20060106000A1 (en) *	2004-07-06	2006-05-18	Claude Nicolau	Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) *	2004-07-06	2010-06-29	NormOxys, Inc	Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
PL1863495T3 (pl) *	2005-03-18	2015-06-30	Normoxys Inc	Sól wapniowa 1,6:2,3:4,5-tripirofosforanu mioinozytolu jako efektor allosteryczny hemoglobiny w leczeniu raka
CN101784193A (zh) *	2007-05-01	2010-07-21	诺尔姆奥克西斯公司	促红细胞生成素互补或替代

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545632A (en) *	1984-10-23	1996-08-13	Perstorp Ab	Method of treating retroviral disease
US5128332A (en) *	1984-10-23	1992-07-07	Perstorp Ab	Method of treating cardiovascular diseases using inositoltrisphosphate
SE465305B (sv) *	1986-04-16	1991-08-26	Perstorp Ab	Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US5023248A (en) *	1984-10-23	1991-06-11	Perstorp Ab	Method of treating diabetes with inositol triphosphate
SE465951B (sv) *	1984-10-23	1991-11-25	Perstorp Ab	Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5015634A (en) *	1986-04-16	1991-05-14	Perstorp Ab	Method of treating tissue damage with inositol triphosphate
US5330979A (en) *	1984-10-23	1994-07-19	Perstorp Ab	Method of treating renal disorders with inositoltriphosphate
US5407924A (en) *	1984-10-23	1995-04-18	Perstorp Ab	Method of treating pain using inositol triphosphate
US5057507A (en) *	1986-04-16	1991-10-15	Perstorp Ab	Method of alleviating bone damage with inositoltriphosphate
US5135923A (en) *	1986-04-16	1992-08-04	Perstorp Ab	Method of treating cardiovascular diseases
SE8605063D0 (sv) *	1986-11-26	1986-11-26	Matti Siren	Derivatives of cyclohexane
US4997761A (en) *	1987-10-06	1991-03-05	Houston Biotechnology Incorporated	Phosphatidyl treatment of viral disease
US5082833A (en) *	1988-06-30	1992-01-21	Shamsuddin Abulkalam M	Reduction of cell proliferation and enhancement of nk-cell activity

1993
- 1993-11-22 SE SE9303853A patent/SE502989C2/sv not_active IP Right Cessation
1994
- 1994-11-18 WO PCT/SE1994/001091 patent/WO1995014475A1/en not_active Ceased
- 1994-11-18 DE DE69432124T patent/DE69432124D1/de not_active Expired - Lifetime
- 1994-11-18 EP EP95901674A patent/EP0730459B1/de not_active Expired - Lifetime
- 1994-11-18 AT AT95901674T patent/ATE232387T1/de not_active IP Right Cessation
- 1994-11-18 JP JP51499095A patent/JP3769011B2/ja not_active Expired - Fee Related
- 1994-11-18 US US08/648,175 patent/US5846957A/en not_active Expired - Fee Related
- 1994-11-18 AU AU10816/95A patent/AU1081695A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO1995014475A1 (en)	1995-06-01
US5846957A (en)	1998-12-08
JP3769011B2 (ja)	2006-04-19
ATE232387T1 (de)	2003-02-15
AU1081695A (en)	1995-06-13
EP0730459A1 (de)	1996-09-11
SE9303853D0 (sv)	1993-11-22
EP0730459B1 (de)	2003-02-12
JPH09505579A (ja)	1997-06-03
SE9303853L (sv)	1995-05-23
DE69432124D1 (de)	2003-03-20

Legal Events

Date

Code

Title

Description

2001-07-16

NUG

Patent has lapsed

Ref document number: 9303853-7

Format of ref document f/p: F

Publication	Publication Date	Title
Thayer	2012	Organometallic compounds and living organisms
KR0180019B1 (ko)	1999-03-20	개량된 화학적 화합물
SE502989C2 (sv)	1996-03-04	Användning av en inositoltrisfosfatester för beredning av läkemedel
US4602037A (en)	1986-07-22	Xanthates and antiviral use thereof
SE503122C2 (sv)	1996-03-25	Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
US20050256090A1 (en)	2005-11-17	Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes
CZ291823B6 (cs)	2003-06-18	Kovalentní lipidické konjugáty fosfonokarbonových kyselin, jejich výroba a jejich použití jako antivirového léčiva
US5545632A (en)	1996-08-13	Method of treating retroviral disease
WO1996014065A9 (en)	1996-09-12	Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity
KR20170103023A (ko)	2017-09-12	암 치료를 위한 유기 비소 화합물 및 방법
EP0316117A1 (de)	1989-05-17	Antivirale Verbindungen, solche Verbindungen enthaltende Zusammensetzungen und Verfahren zur Behandlung
US3732295A (en)	1973-05-08	Trimethoxybenzoyl-aminoalkanoic acids
RU2178418C2 (ru)	2002-01-20	Ковалентные конъюгаты липидов с фосфонокарбоновой кислотой, их получение и применение в качестве антивирусных лекарственных средств
AU679676B2 (en)	1997-07-10	Ion pairs of hypericin compounds having antiviral activity
JP2997552B2 (ja)	2000-01-11	２−ホルミルベンジルホスホン酸誘導体およびその製造方法
US6774254B2 (en)	2004-08-10	Gold complexes
SE502990C2 (sv)	1996-03-04	Användning av en inositoltrisfosfatester för beredning av ett smärtstillande läkemedel
SE501793C2 (sv)	1995-05-15	Användning av inositoltrisfosfat för beredning av läkemedel
US5278152A (en)	1994-01-11	2-formylbenzylphosphonic acid derivatives useful for the treatment of diseases caused by viruses
JP2006520763A (ja)	2006-09-14	４級ケリドニン及びアルカロイド誘導体類、それらの製造法、及び医薬の製造でのそれらの使用
WO2001077121A1 (en)	2001-10-18	Gold complexes
WO1996016629A2 (en)	1996-06-06	Phosphinic creatine compounds having antiviral activity
EP0360619A2 (de)	1990-03-28	Antivirale Wirkstoffe
Tsou et al.	1976	Synthesis of aziridinyallylaminophosphine oxides and sulfides as potential adjuvant cancer chemotherapeutic agents
CN112175008A (zh)	2021-01-05	替诺福韦混合氨基磷酸酯化合物、其药物组合物及其应用